# Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

> **NCT00022906** · PHASE1 · UNKNOWN · sponsor: **Corixa Corporation** · enrollment: 24 (—)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Iodine-131 Anti-B1 Antibody

## Key facts

- **NCT ID:** NCT00022906
- **Lead sponsor:** Corixa Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 24 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022906, "Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00022906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*